ArticleCell death & disease2026
MARCKS as a mediator and target for pathological tunneling nanotubes between patient-derived glioblastoma cells and astrocytes.
Article in Cell death & disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
During glioblastoma (GBM) progression, therapeutic resistance is influenced by a heterogeneous network of tumor- and tumor-promoting subpopulations within the tumor microenvironment. Therapeutic interventions against tumor cells, such as chemoradiotherapy, can further induce adaptive defense mechanisms mediated by sophisticated intercellular communication and aberrant signaling pathways. Tunneling nanotubes (TNTs) have emerged as key mediators of this process, promoting tumor cell survival through metabolic rescue while enabling the recruitment and reprogramming of surrounding normal cells into tumor-supportive phenotypes. This dynamic is exemplified in GBM, where TNT-mediated interactions between brain tumor-initiating cells (BTICs) and normal human astrocytes (NHAs) highlight the need to elucidate the molecular mediators underlying this crosstalk. Myristoylated Alanine Rich C-Kinase Substrate (MARCKS) has never been investigated as a potential regulator of TNTs despite several overlapping signaling pathways and its influence on GBM therapeutic resistance. In the present study, we demonstrate a role for the MARCKS effector domain (ED) and PKC activation in the formation and functionality of TNTs between PTEN-null GBM BTICs and NHAs. We employ a MARCKS phosphorylation site (MPS) peptide derived from MARCKS effector domain (MED2), PKC-targeting drugs, and an inducible MARCKS ED U87 model to elucidate a potential role for MARCKS phosphorylation and PKC in TNT regulation between GBM cells (i.e., BTICs or U87s) and NHAs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.